Breast cancer molecular profiling with single sample predictors: a retrospective analysis
- PMID: 20181526
- DOI: 10.1016/S1470-2045(10)70008-5
Breast cancer molecular profiling with single sample predictors: a retrospective analysis
Abstract
Background: Microarray expression profiling classifies breast cancer into five molecular subtypes: luminal A, luminal B, basal-like, HER2, and normal breast-like. Three microarray-based single sample predictors (SSPs) have been used to define molecular classification of individual samples. We aimed to establish agreement between these SSPs for identification of breast cancer molecular subtypes.
Methods: Previously described microarray-based SSPs were applied to one in-house (n=53) and three publicly available (n=779) breast cancer datasets. Agreement was analysed between SSPs for the whole classification system and for the five molecular subtypes individually in each cohort.
Findings: Fair-to-substantial agreement between every pair of SSPs in each cohort was recorded (kappa=0.238-0.740). Of the five molecular subtypes, only basal-like cancers consistently showed almost-perfect agreement (kappa>0.812). The proportion of cases classified as basal-like in each cohort was consistent irrespective of the SSP used; however, the proportion of each remaining molecular subtype varied substantially. Assignment of individual cases to luminal A, luminal B, HER2, and normal breast-like subtypes was dependent on the SSP used. The significance of associations with outcome of each molecular subtype, other than basal-like and luminal A, varied depending on SSP used. However, different SSPs produced broadly similar survival curves.
Interpretation: Although every SSP identifies molecular subtypes with similar survival, they do not reliably assign the same patients to the same molecular subtypes. For molecular subtype classification to be incorporated into routine clinical practice and treatment decision making, stringent standardisation of methodologies and definitions for identification of breast cancer molecular subtypes is needed.
Funding: Breakthrough Breast Cancer, Cancer Research UK.
2010 Elsevier Ltd. All rights reserved.
Comment in
-
Molecular subtyping of breast cancer: ready to use?Lancet Oncol. 2010 Apr;11(4):306-7. doi: 10.1016/S1470-2045(10)70036-X. Lancet Oncol. 2010. PMID: 20359657 No abstract available.
-
SSP reliability for breast cancer.Nat Rev Clin Oncol. 2010 May;7(5):240. doi: 10.1038/nrclinonc.2010.56. Nat Rev Clin Oncol. 2010. PMID: 20432524 No abstract available.
-
The importance of platform annotation in interpreting microarray data.Lancet Oncol. 2010 Aug;11(8):717. doi: 10.1016/S1470-2045(10)70115-7. Lancet Oncol. 2010. PMID: 20688273 No abstract available.
-
Clinical implementation of the intrinsic subtypes of breast cancer.Lancet Oncol. 2010 Aug;11(8):718-9; author reply 720-1. doi: 10.1016/S1470-2045(10)70176-5. Lancet Oncol. 2010. PMID: 20688274 No abstract available.
-
The importance of gene-centring microarray data.Lancet Oncol. 2010 Aug;11(8):719-20; author reply 720-1. doi: 10.1016/S1470-2045(10)70174-1. Lancet Oncol. 2010. PMID: 20688275 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
